Protalix BioTherapeutics, Inc. (PLX)
- Previous Close
2.8400 - Open
2.8400 - Bid 2.7100 x 1000
- Ask 2.8000 x 800
- Day's Range
2.7201 - 2.8400 - 52 Week Range
0.8200 - 3.1000 - Volume
742,866 - Avg. Volume
715,475 - Market Cap (intraday)
224.961M - Beta (5Y Monthly) -0.05
- PE Ratio (TTM)
68.25 - EPS (TTM)
0.0400 - Earnings Date May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.50
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
www.protalix.comRecent News: PLX
View More
Performance Overview: PLX
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PLX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PLX
View MoreValuation Measures
Market Cap
217.08M
Enterprise Value
187.78M
Trailing P/E
68.25
Forward P/E
6.20
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.14
Price/Book (mrq)
5.02
Enterprise Value/Revenue
3.52
Enterprise Value/EBITDA
28.80
Financial Highlights
Profitability and Income Statement
Profit Margin
5.49%
Return on Assets (ttm)
3.10%
Return on Equity (ttm)
7.64%
Revenue (ttm)
53.4M
Net Income Avi to Common (ttm)
2.93M
Diluted EPS (ttm)
0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
34.83M
Total Debt/Equity (mrq)
12.79%
Levered Free Cash Flow (ttm)
5.43M
Research Analysis: PLX
View MoreResearch Reports: PLX
View MoreDaily – Vickers Top Buyers & Sellers for 10/23/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/06/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/14/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.